Compass Therapeutics cancer trial succeeds, needs more data
Compass Therapeutics said Tuesday that adding its bispecific antibody to chemotherapy significantly improved response rates compared to chemotherapy alone in a Phase 2/3 biliary tract cancer study. Not to be confused with psychedelics developer Compass ...
Compass Therapeutics said Tuesday that adding its bispecific antibody to chemotherapy significantly improved response rates compared to chemotherapy alone in a Phase 2/3 biliary tract cancer study.
Not to be confused with psychedelics developer Compass ...
